This has been translated from Japanese in the interest of preserving information. Source

The evolution of medicine has improved the health of billions of people in the last 50 years. More than 90% of this advanced medicine is the well-known Wayland’s health sector. Since launching its first medical program in 2022, Weyland has become an unbeatable company in improving health, treating fatal diseases and developing better surgical procedures. did. In the past 50 years, advancements in Weyland’s pharmaceutical and genetics have increased lifespan by 16% on Earth, and we have shown an amazing 21% lifespan extension, especially for Weyland employees.

Today, Weyland’s diverse health sector employs more than 80 million scientists, researchers, engineers, doctors and nurses. Weyland’s healthcare workers treat more than 3 billion people a year in thousands of hospitals and regions across the Galactic region.

In 2034, Weyland’s health sector sponsored a $ 500 billion grant for genetic engineering.

Financial support for researchers working on discoveries in the process of gene selection has important implications for contemporary gender and reproductive health worldwide. As a result, in the biotech area, Wayland’s medicines are used by more hospitals, extraterrestrial colonial medical facilities and medical teams than any other brand. In addition, with minimally invasive techniques, our latest line of operating room equipment has been further upgraded to increase the efficiency of automation and diagnostics.

In addition, Wayland has expanded its portfolio of home and office innovations. The Mobile Trauma Diagnostic Center (MEDiC) is located in most homes, classrooms, warehouses, distribution centers, etc. in the Galactic System.

Since the discovery of cures for common cancers, Weyland is passionately pursuing a vision of a disease-free society through innovation and investment in medical research, and aims to build a better world through health improvement. .


This year, Weyland announced the latest FDA-approved medical pod 720i. The 720i can perform a wide range of surgical procedures with diagnosis and treatment, and 3D human scanning and micro laser dissection. Feasible medical procedures include various procedures ranging from diagnosis and treatment of infections by injection of concentrated antibiotics, treatment of basic wounds, surgery for appendicitis, laparoscopic surgery, cesarean surgery. Currently, a dozen medical pods 720i are manufactured and deployed in each of the Wayland Industries areas for commercial testing.


MEDiC is an important tool for public facilities and homes. MEDiC eliminates anxiety and delivers peace of mind. Operation is as easy as opening the wall-mounted case and taking out the diagnostic vest. When worn by the patient, MEDiC will diagnose a variety of injuries, and if any injuries are detected, blood tests are performed and results are returned in minutes. Responding emergency nurses have immediate access to patient information from MEDiC and can transfer it to the nearest medical facility. MEDiC can be operated by any adult citizen, saving millions of lives.


The anti-gravity recovery chamber is a very advanced technology and is used in hospitals and rehabilitation centres. Studies have shown that in anti-gravity conditions, patients recover 70% faster from traumatic injury and disease. Weyland scientists have designed a room-sized facility that produces a certain level of anti-gravity. Patients can enjoy the benefits of anti-gravity therapy while lying comfortably in the bed. This product is currently available for limited release only in major cities on earth.


Another remarkable innovation by WEyland scientists is the synapse-building machine. Accurate and fine electrical nerve stimulation activates the dormant neurons of the dead or dying patient’s brain tissue. Because this sensitive technology is a matter of caution, its implementation is limited to only a very limited number of doctors and scientists. The nine existing rebuild machines have been used for experimental purposes only at medical schools and biotechnology research centres for the past two years and are under FDA review.